Medindia LOGIN REGISTER
Medindia
Advertisement

Patients' Driving Skills Improved by Common Alzheimer's Drug

by Kathy Jones on June 11, 2010 at 5:05 PM
 Patients'  Driving  Skills Improved by Common  Alzheimer's  Drug

A type of medication often prescribed for Alzheimer's disease (AD), improved some cognitive skills in patients with mild AD, a new study has found.

The study from Rhode Island Hospital demonstrated that cholinesterase inhibitors (ChEI) improved some computerized tests of executive function and visual attention, including a simulated driving task in patients. in patients.

Advertisement

"Because many patients receiving a diagnosis of AD continue to drive in its early stages, it is critical that we assess driving safety among this population and identify therapies that may improve driving abilities. ChEIs are commonly prescribed for AD, yet little is known about how their potential treatment effects might impact a driver's skills," said Lori Daiello, PharmD, a research associate at the Rhode Island Hospital Alzheimer's Disease and Memory Disorders Center (ADMDC).

The primary analysis consisted of comparing the test performance of AD patients before starting ChEI treatment and after three months of therapy.n a secondary cross-sectional analysis, the subjects' pre-ChEI computerized test performances were compared to the abilities of a matched group of AD patients who had performed the same computerized tests while receiving stable ChEI therapy.
Advertisement

The treatment showed three results - improvement in the ability to accurately maintain lane position during the simulated driving task, visual search task was performed without simulated driving improved target detection accuracy in the visual search task and quicker visual search response times in both the pre- and post-treatment comparison and cross-sectional comparisons.

The investigators note that while the result is encouraging, this study lacked a direct measure of on-road driving performance and warrants further investigation.

The study is published in the June 2010 edition of the Journal of Clinical Psychopharmacology.

Source: ANI
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Drug News

Can a Needle-Free Patch Transform Zika Protection?
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Apotransferrin's Potential in Early Stroke Therapy Revealed
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Patients' Driving Skills Improved by Common Alzheimer's Drug Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests